Background: Although many reports have elucidated pathophysiological characteristics of abnormal bone metabolism in patients with type 2 diabetes mellitus (DT2), determinants of bone mineral density (BMD) in patients with DT2 are still controversial. Methods: We examined 168 Belarussian men 45-60 years of age. Plasma total cholesterol (TC), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, triglycerides, hemoglobin A 1c (HbA 1c ), immunoreactive insulin, and C-reactive protein concentrations were assessed. BMD was measured using dual energy X-ray densitometry of the lumbar spine (L 1 -L 4 ). Total testosterone (TT) and sex hormone-binding globulin were measured, and free testosterone (FT) was calculated. Results: Using univariate linear regression analysis, BMD of the lumbar spine was significantly correlated with FT (rs0.32, p-0.01) and TT (rs0.36, p-0.01). Using multiple linear regression analysis adjusted for confounding factors, BMD was significantly correlated with TT (bs0.23, p-0.001) and TC (bs-0.029, ps0.005). Age (bs0.005, ps0.071), body mass index (bs0.005, ps0.053), HbA 1c (bs-0.002, ps0.72) and duration of diabetes (bs0.001, ps0.62) were not significantly correlated with BMD. Conclusions: Our data indicate that androgens are independent determinants of BMD in male patients with DT2.
Introduction
Although many reports have elucidated the pathophysiological characteristics of abnormal bone metabolism in patients with type 2 diabetes mellitus (DT2), determinants of bone mineral density (BMD) in patients with DT2 are still controversial (1, 2) . In recent years, the prevalence of osteoporosis in men has been increasing (3) . Although the frequency of osteoporosis is lower than that in women, hip and spine fractures in men are associated with higher morbidity and mortality compared with women (31%-38% vs. 12%-28%, respectively) (4), and men are twice as likely to be institutionalized after experiencing one of these fractures (5, 6) .
Sex steroids play an important role in the maintenance of bone metabolism. In a previous study, low androgen concentrations were reported to be a predictor of bone loss in men (7) . Furthermore, serum concentrations of testosterone have been reported to be lower in men with diabetes than in nondiabetic men (8) . However, hypogonadism is commonly related to age-related changes in sex hormones of the elderly. These changes are usually biochemically defined and generally unaccompanied by clinical evidence of hypogonadism. Estrogen deficiency can also occur in normal older men as a consequence of aging, and serum estradiol appears to have an important effect on bone health in men (9) . Therefore, hypogonadism-induced osteoporosis in men seems to be related to the physiological effects of serum testosterone and estradiol.
In this study, we investigated the determinants of BMD in male patients with DT2 to establish future strategies for the prevention of fractures due to osteoporosis in these patients.
Subjects and methods

Subjects
Ethical approval was obtained from the special committee of The Republican Research Centre for Radiation Medicine and Human Ecology (Gomel, Republic of Belarus). We investigated 168 Belarussian men with DT2 who presented consecutively to this institute. Patients aged 45-60 years with DT2 and a body mass index (BMI) between 18.5 and 40 kg/m 2 were included in this study. Criteria for the diagnosis of DT2 included symptoms of diabetes (excessive urination, constant thirst, tiredness, blurred vision) and a fasting plasma glucose indicative of impaired fasting glucose (6.1 mmol/ L) and a casual plasma glucose concentration G11.1 mmol/L. Casual was defined as any time of day without regard to time of the last meal.
Patients with thyroid disease and liver cirrhosis were excluded. Written informed consent was obtained from all men. All patients were treated with diet, oral antidiabetic drugs (biguanides and sulfonylureas), and/or insulin. Values are mean"standard deviation or median (25th-75th percentile). OHA, oral hypoglycemic agents.
Demographic parameters and patient information were collected; height and weight were measured, and BMI was calculated. Data related to the duration of diabetes and given medications were also collected. BMD was evaluated using dual-energy X-ray absorptiometry (GE Lunar Prodigy Advance, New York, USA). BMD was measured at the lumbar spine (L 1 -L 4 ).
Biochemical measurements
Fasting venous blood samples were collected in the morning (before 10 a.m.). Plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) concentrations were measured using standard enzymatic methods. Low-density lipoprotein cholesterol (LDL-C) and very low-density lipoprotein cholesterol (VLDL-C) were calculated using the Friedewald et al. (10) equation. Hemoglobin A 1c (HbA 1c ) was measured using high-performance liquid chromatography. Immunoreactive insulin (IRI) was measured by radioimmunoassay (RIA) using DSL 10-1600 (ACTIV ᭨ , Diagnostic Systems Laboratories, Inc., Webster, TX, USA). C-reactive protein (CRP) was measured using a latex particle-enhanced turbidimetric immunoassay.
Serum total testosterone (TT) was measured using a solid-phase RIA wintra-assay coefficient of variation (CV) 4.3% and inter-assay CV 9.8%x. The lower limit of normal for TT is 12 nmol/L. Free testosterone (FT) was calculated from sex hormone-binding globulin (SHBG) and TT using the ''Free and Bioavailable Testosterone calculator'' (11). SHBG, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured using a chemiluminescent immunometric assay (SHBG, intra-assay CV 3.1% and inter-assay CV 4.1%; LH, intra-assay CV 4.2% and inter-assay CV 5.5%; FSH, intra-assay CV 3.5% and inter-assay CV 3.7%). All samples obtained from each subject were assayed in the same run for each hormone to exclude inter-assay variation from changes in hormone concentrations within subjects.
Statistical analysis
Data are presented as the mean"standard deviation (SD), or median (25th-75th percentile). Spearman rank correlation analysis was performed to evaluate the association between BMD and other parameters. Multivariate linear regression analysis was performed to evaluate the association between BMD and other parameters adjusted for age, BMI, HbA 1c , duration of diabetes, TC, and log FT. Because FT was distributed in a skewed manner, logarithmic transformation was performed for multivariate linear regression analysis. A p-value -0.05 was considered statistically significant.
Results
The characteristics of study participant are shown in Table  1 . One hundred and eight patients (64%) had below-normal testosterone (-12 nmol/L). Forty-three patients (25.6%) had either increased LH or increased FSH concentrations (10 had increased concentrations of both LH and FSH, six had high LH only, and 27 had high FSH only).
There were no significant differences in BMD between smokers and non-smokers (ps0. 19, t-test (Table 3) .
Discussion
In recent years, several studies have reported a relationship between the reduction in circulating concentrations of testosterone and bone loss in elderly men and have confirmed the presence of androgen receptors in osteoblasts and osteocytes (12) (13) (14) (15) (16) . Androgens have been shown to inhibit bone resorption through a decrease in IL-6 production by osteoblasts (17) , inhibition of the effect of parathyroid hormone (PTH) on osteoblasts (18) , or through the inhibition of osteoclastogenesis (19) . Apart from the direct action of circulating androgens, there is evidence that the cellular effect of testosterone is mediated through its metabolites formed locally in bone. Both aromatase and 5a-reductase are present in bone tissue (20) . Conversion of androgens to estrogen by the enzyme aromatase is important for many of androgen's actions on bone (21) . At the tissue level, estrogen suppresses bone turnover and maintains a balance between bone formation and bone resorption, and estrogen increases osteoblast differentiation and function, but decreases osteoclast formation and activity at the cellular level (22) . Although some authors have identified TT as a strong predictor of BMD, this relationship remains controversial (23) . In this study, we showed that serum FT concentration is independently correlated with BMD. Testosterone is necessary for the aromatization and formation of estrogen in the testes and surrounding tissue (24) .
Previous studies have shown that estrogen is an important determinant of BMD in men and is correlated with testosterone (25) . However, in our study univariate linear regression analysis showed that BMD was not significantly correlated with total estradiol concentration (rs-0.13, ps0.08). This discrepancy might be due to our measurement of ''total'' and not ''free'' estradiol concentrations (26) . This is because serum total estradiol concentrations do not reflect activity at the tissue level, as peripherally formed estradiol is partially metabolized in situ; thus, not all of the estradiol enters the general circulation.
Bjornerem et al. reported that log FT concentrations were positively associated with BMD, whereas low SHBG concentrations were inversely associated with BMD (27) . Testosterone concentrations in men are known to decline with age, and SHBG concentrations are known to rise in older men and women (28) . In this study, we found that SHBG was inversely associated with BMD by univariate correlation, but there was no significant association between BMD and SHBG by multivariate linear regression analysis adjusted for confounding factors.
The relationship of long-term blood glucose control to BMD is still controversial. It has been speculated that osteoporosis might be a complication of diabetes resulting from cumulative, long-term poor control (29) . We did not find a relationship between the duration of diabetes and BMD, or correlation between HbA 1c and BMD. However, the absence of a relationship with HbA 1c might be attributable to the use of a single HbA 1c measurement.
Tanko et al. (30) found significant inverse correlation between serum cholesterol and BMD in postmenopausal women. They proposed that estrogen could have direct effects on bone and cholesterol metabolism. It was shown that lipids accumulate around bone vessels (31). Parhami et al. found that oxidized lipids and hyperlipidemia may inhibit osteoblastic differentiation (32) . Because immature osteoblasts are located immediately adjacent to the subendothelial matrix of bone vessels, these cells may be susceptible to damage caused by products of lipid oxidation. Additionally, oxidized lipids may induce endothelial expression of macrophage-colony stimulating factor, a potent stimulator of osteoblastic differentiation (33) . In a recent study, Kha et al. (34) showed that specific oxysterols -products of cholesterol oxidation -act synergistically with bone morphogenic protein 2 to induce osteogenic differentiation. In our study, we also found significant inverse correlation between serum cholesterol and BMD in male patients with DT2, adjusted for confounding factors (bs-0.029, ps0.005). Further, evaluation will be needed to clarify the mechanisms of this relationship.
Several limitations need to be addressed in the present study. First, our sample size was relatively small. In addition, we assessed BMD using dual-energy X-ray absorptiometry instead of ultrasound. It is known that BMD assessed by dual energy X-ray absorptiometry (DXA) is an established marker for osteoporosis. However, in recent years, ultrasound absorptiometry has emerged as a possible alternative to DXA because ultrasound measurement is free from radiation exposure (35) . In addition, CT-imaging of the lumbar spine provides superior anatomical imaging of the osseous (bony) structures of the spine when more detailed imaging of the bony architecture is needed. Thus, computed tomography (CT) imaging may have provided different data on BMD. Moreover, we did not evaluate markers of bone formation, physical activity, or alcohol consumption. Further studies are needed to clarify the contribution of androgens to BMD in patients with DT2.
In conclusion, we showed that androgens are important for bone health in male patients with DT2. To fully exploit opportunities for hormone-related management of osteoporosis in men, a better understanding of the precise nature of their action on BMD is needed.
